

Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – January 12, 2010 @ 6:00 p.m.

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

- 1. Call To Order**
 - A. Roll Call – Dr. Graham

Items to be presented by Dr. Muchmore, Chairman:

- 2. Public Comment Forum**
 - A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

- 3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
 - A. December 8, 2010 DUR Minutes – Vote
 - B. December 9, 2010 DUR Recommendation Memorandum

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

- 4. Update on DUR / Medication Coverage Authorization Unit – See Appendix B.**
 - A. Retrospective Drug Utilization Review Response for September 2010
 - B. Medication Coverage Activity Audit for December 2010
 - C. Pharmacy Help Desk Activity Audit for December 2010

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 5. Action Item – Vote to Prior Authorize Zyflo CR[®] – See Appendix C.**
 - A. COP Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman

- 6. Action Item – Vote to Prior Authorize Latuda[™] – See Appendix D.**
 - A. COP Recommendations

Items to be presented by Dr. Chonlahan, Dr. Muchmore, Chairman

- 7. 30 Day Notice to Prior Authorize Benign Prostate Hyperplasia (BPH) Products – See Appendix E.**
 - A. COP Recommendations

Items to be presented by Dr. Robinson, Dr. Muchmore, Chairman

8. **Action Item – Annual Review of Hypnotic Medications and 30 Day Notice to Prior Authorize Silenor[®] – See Appendix F.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorizations Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details
 - G. Silenor[®] Product Details

Items to be presented by Dr. Sipols, Dr. Muchmore, Chairman

9. **Action Item – Annual Review of Antihypertensives and 30 Day Notice to Prior Authorize Tribenzor[®], Tekamlo[®], Nexiclon XR[®], and Catapres-TTS[®] – See Appendix G.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorizations Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details
 - G. New Product Details

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

10. **Action Item – Annual Review of ADHD Medications and 30 Day Notice to Prior Authorize Kapvay[®] and Xyrem[®] – See Appendix H.**
 - A. Current Authorization Criteria
 - B. Utilization Review
 - C. Prior Authorizations Review
 - D. Market News and Update
 - E. COP Recommendations
 - F. Utilization Details
 - G. New Product Details

Items to be presented by Dr. Graham, Dr. Muchmore, Chairman

11. **FDA and DEA Updates – See Appendix I.**

12. **Future Business**
 - A. Utilization Review of Diabetes Products
 - B. Annual Review of Triptans
 - C. Annual Review of Antiemetics
 - D. New Product Reviews

13. **Adjournment**